Amino acid derivatives and their uses
Provided are compounds described by the Formula I: wherein: R 1 is a linear or branched, saturated or unsaturated aliphatic group having from 5 to 22 carbon atoms; R 2 is selected from the group consisting of the functional groups: —NH 2 ; and salts thereof; n is from 0 to 4; and R 3 is a linear or branched, saturated or unsaturated aliphatic group having from 1 to 6 carbon atoms. Also provided are compositions comprising, and methods of use of, the compounds of the present invention.
1. A method of inhibiting plaque in an oral cavity comprising contacting a surface of the oral cavity with a compound selected from the group consisting of:
[amino({[4-(methylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-(ethylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-(hexylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(methylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(ethylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(hexylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-(methylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[4-(ethylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[4-(hexylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[5-dodecanamido-5-(ethylcarbamoyl)pentyl]amino})methylidene]azanium,
N-[5-amino-1-(ethylcarbamoyl)pentyl]dodecanamide,
N-[4-amino-1-(ethylcarbamoyl)butyl]dodecanamide
and
N-[2-amino-1-(ethylcarbamoyl)ethyl]dodecanamide.
2. The method of claim 1 wherein the compound is
[amino({[4-dodecanamido-4-(ethylcarbamoyl)butyl]amino})methylidene]azanium.
3. A method of inhibiting plaque in an oral cavity comprising contacting a surface of the oral cavity with a compound selected from the group consisting of:
[amino({[4-(methylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-(ethylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-(hexylcarbamoyl)-4-octanamidobutyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(methylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(ethylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-dodecanamido-4-(hexylcarbamoyl)butyl]amino})methylidene]azanium,
[amino({[4-(methylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[4-(ethylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[4-(hexylcarbamoyl)-4-octadecanamidobutyl]amino})methylidene]azanium,
[amino({[5-dodecanamido-5-(ethylcarbamoyl)pentyl]amino})methylidene]azanium,
and
N-(5-guanidino-1-oxo-1-(undecylamino)pentan-2-yl)octanamide.
4. A method of inhibiting plaque in an oral cavity comprising contacting a surface of the oral cavity with a compound selected from the group consisting of:
N-[5-amino-1-(ethylcarbamoyl)pentyl]dodecanamide,
N-[2-amino-1-(ethylcarbamoyl)ethyl]dodecanamide,
N-[4-amino-1-(ethylcarbamoyl)butyl]dodecanamide,
N-(5-amino-1-(hexylamino)-1-oxopentan-2-yl)dodecanamide,
N-(5-amino-1-oxo-1-(undecylamino)pentan-2-yl)octanamide
and
N-(5-amino-1-(octylamino)-1-oxopentan-2-yl)octanamide.